Results 141 to 149 of about 179,166 (149)

Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. [PDF]

Commun Med (Lond)
Pan B, Mountford SJ, Kiso M, Anderson DE, Papadakis G, Jarman KE, Tilmanis DR, Maher B, Tran T, Shortt J, Yamayoshi S, Kawaoka Y, Thompson PE, Greenall SA, Warner N.   +14 more
europepmc   +1 more source

A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
A CTGF‐LYTAC nanoplatform is developed to selectively degrade connective tissue growth factor (CTGF) in triple‐negative breast cancer (TNBC), inhibiting TGF‐β signaling and cell interactions in the tumor microenvironment (TME). This strategy effectively suppresses tumor growth and metastasis, outperforming antibody‐based therapy.
Jia‐Yi Lin, Ye Wu, Xiao‐Hui Liang, Min Tang, Xin Sun, Sheng‐Xin Lu, Jin‐Mei Jin, Xin Guo, Bei Wang, Hong‐Zhuan Chen, Wei‐Dong Zhang, Xin Luan   +11 more
wiley   +1 more source

Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections. [PDF]

Pharmaceutics
Halawa M, ElSayed RMR, Aderibigbe T, Newman PM, Reid BE, Carabetta VJ.   +5 more
europepmc   +1 more source

Temporal Trends in HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Istanbul, Türkiye (2021-2024): A Next-Generation Sequencing Study. [PDF]

Viruses
Yaman M, Gülcen BS, Özgüler K, Köksal MO, Tekol SD, İlki A.   +5 more
europepmc   +1 more source

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier. [PDF]

Antimicrob Agents Chemother
Zhao L, Li C, Wang M, Zhou M, Jiang L, Zhang W, Yu J, Wang W, Zhou K, Pan K, Lam H-Y, Hung IF-N, Chan K-H, Liu L, Wang F, Zhao X, Chen Y.   +16 more
europepmc   +1 more source

Susceptibility to Lenacapavir Among Newly Diagnosed HIV-Positive Patients Followed Up in Mozambique That Presented With Primary Antiretroviral Resistance to Other Classes. [PDF]

J Med Virol
Sebastião CS, Bathy J, Nhampossa T, Santos A, Miranda M, Manhiça NM, Bila R, Vubil D, Seabra S, O Martins MR, Giovanetti M, Gomes P, Pingarilho M, Abecasis AB, Pimentel V.   +14 more
europepmc   +1 more source

Assessing HIV-1 subtype C infection dynamics, therapeutic responses and reservoir distribution using a humanized mouse model. [PDF]

Front Immunol
Kaginkar S, Remling-Mulder L, Sahoo A, Pandey T, Gurav P, Sutar J, Singh AK, Barnett E, Panickan S, Akkina R, Patel V.   +10 more
europepmc   +1 more source

Lenacapavir for multidrug-resistant HIV-1 infection. [PDF]

Aust Prescr
europepmc   +1 more source